Last reviewed · How we verify
Supervised primaquine treatment
Supervised primaquine treatment is a 8-aminoquinoline antimalarial Small molecule drug developed by Menzies School of Health Research. It is currently FDA-approved for Malaria caused by Plasmodium vivax (radical cure including hypnozoite elimination), Malaria caused by Plasmodium ovale (radical cure including hypnozoite elimination), Malaria caused by Plasmodium malariae.
Primaquine is an 8-aminoquinoline antimalarial that eliminates malaria parasites by generating reactive oxygen species that damage parasite DNA and mitochondria.
Primaquine is an 8-aminoquinoline antimalarial that eliminates malaria parasites by generating reactive oxygen species that damage parasite DNA and mitochondria. Used for Malaria caused by Plasmodium vivax (radical cure including hypnozoite elimination), Malaria caused by Plasmodium ovale (radical cure including hypnozoite elimination), Malaria caused by Plasmodium malariae.
At a glance
| Generic name | Supervised primaquine treatment |
|---|---|
| Sponsor | Menzies School of Health Research |
| Drug class | 8-aminoquinoline antimalarial |
| Target | Plasmodium parasite mitochondria and DNA |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Primaquine works against both the erythrocytic (blood) and exoerythrocytic (liver) stages of malaria parasites, with particular efficacy against hypnozoites—dormant liver forms of P. vivax and P. ovale that cause relapse. The drug is metabolized to active metabolites that disrupt parasite metabolism and induce oxidative stress. Supervised administration ensures adherence and monitoring for glucose-6-phosphate dehydrogenase (G6PD) deficiency-related hemolysis.
Approved indications
- Malaria caused by Plasmodium vivax (radical cure including hypnozoite elimination)
- Malaria caused by Plasmodium ovale (radical cure including hypnozoite elimination)
- Malaria caused by Plasmodium malariae
Common side effects
- Hemolytic anemia (in G6PD-deficient patients)
- Abdominal pain
- Nausea
- Methemoglobinemia
- Headache
Key clinical trials
- Postpartum Primaquine in Breast Milk (PHASE4)
- Tafenoquine and Primaquine in Colostrum and Breast Milk (PHASE4)
- P.Vivax Treatment Trial (PHASE1, PHASE2)
- Efficacy of 3 Regimens of Chloroquine and Primaquine for Treatment of P. Vivax Malaria, Cruzeiro do Sul, Acre, Brazil (NA)
- IMPROV (Improving the Radical Cure of Vivax Malaria) (NA)
- A Randomized Controlled Trial on Malaria Primaquine Treatment in Timika, Indonesia (TRIPI) (PHASE4)
- A Trial on Supervised Primaquine Use in Ethiopia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Supervised primaquine treatment CI brief — competitive landscape report
- Supervised primaquine treatment updates RSS · CI watch RSS
- Menzies School of Health Research portfolio CI
Frequently asked questions about Supervised primaquine treatment
What is Supervised primaquine treatment?
How does Supervised primaquine treatment work?
What is Supervised primaquine treatment used for?
Who makes Supervised primaquine treatment?
What drug class is Supervised primaquine treatment in?
What development phase is Supervised primaquine treatment in?
What are the side effects of Supervised primaquine treatment?
What does Supervised primaquine treatment target?
Related
- Drug class: All 8-aminoquinoline antimalarial drugs
- Target: All drugs targeting Plasmodium parasite mitochondria and DNA
- Manufacturer: Menzies School of Health Research — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Malaria caused by Plasmodium vivax (radical cure including hypnozoite elimination)
- Indication: Drugs for Malaria caused by Plasmodium ovale (radical cure including hypnozoite elimination)
- Indication: Drugs for Malaria caused by Plasmodium malariae
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing